Cadrenal plans FDA rare pediatric disease request for tecarfarin in Kawasaki disease

Cadrenal Therapeutics said it plans to ask the FDA for Rare Pediatric Disease Designation for tecarfarin in pediatric patients with Kawasaki disease who develop coronary artery aneurysms and require chronic oral anticoagulation.¹

“Children with large or giant aneurysms due to KD represent an important underserved orphan population,” Quang X. Pham, chief executive officer of Cadrenal, said in a news release. Pham said the company is positioning tecarfarin as a potential alternative to warfarin, although no Kawasaki disease efficacy or safety data were reported in the release.¹

The planned submission is an early regulatory step rather than an approval application. Rare Pediatric Disease Designation applies to serious or life-threatening diseases that primarily affect children and meet rarity criteria in the United States. If granted, and if tecarfarin is later approved for this indication, the sponsor could become eligible for a priority review voucher under the FDA program.^1,2

Kawasaki disease is an acute, self-limited vasculitis that predominantly affects young children and is the leading cause of acquired heart disease in children in developed countries.^3,4 Coronary artery aneurysms are the major long-term complication. The American Heart Association (AHA) notes that approximately 25% of untreated children may develop coronary artery abnormalities, whereas timely treatment with intravenous immunoglobulin reduces that risk substantially.³

The clinical question identified by Cadrenal is narrower than acute Kawasaki disease management. The proposed tecarfarin program would focus on children with coronary artery aneurysms, particularly large or giant aneurysms, who remain at risk for thrombosis and may require long-term antithrombotic therapy. Current AHA guidance supports risk-stratified management based on coronary artery dimensions, including antiplatelet therapy for many patients and anticoagulation with warfarin or low-molecular-weight heparin for those with large or giant aneurysms.³

What is tecarfarin, and how does it work?

Tecarfarin is an oral vitamin K antagonist. Unlike warfarin, which is metabolized through cytochrome P450 pathways, tecarfarin is designed to avoid CYP450 metabolism, a feature the company argues could reduce variability in anticoagulant response.¹ That premise is clinically relevant in pediatrics, where diet, growth, intercurrent illness, drug interactions, and adherence can complicate maintenance of a therapeutic international normalized ratio. However, whether tecarfarin improves time in therapeutic range, bleeding outcomes, or thrombotic outcomes in children with Kawasaki disease has not yet been established in the information released.

Cadrenal described tecarfarin as a late-stage oral anticoagulant also being developed for patients requiring chronic anticoagulation, including those with end-stage kidney disease and those with left ventricular assist devices. The company stated that tecarfarin has received FDA Orphan Drug and Fast Track designations, but the announcement did not specify the indications associated with those prior designations.¹

Next steps

The company also used the announcement to preview its planned presentations at the 2026 BIO International Convention in San Diego. In addition to tecarfarin, Cadrenal said it will discuss CAD-1005, a 12-lipoxygenase inhibitor described by the company as phase 3-ready for heparin-induced thrombocytopenia and advancing toward a phase 2a trial in cardiac surgery–associated acute kidney injury.¹ Those programs are separate from the planned Kawasaki disease request.

For clinicians, the immediate takeaway is that tecarfarin is not approved for Kawasaki disease and that no trial results in this pediatric population were included in the company release. Any future clinical role would depend on FDA feedback, trial design, pediatric pharmacokinetic and pharmacodynamic data, and evidence that anticoagulation control and clinical outcomes are at least comparable with existing approaches.

Important unanswered questions include the age range to be studied, target anticoagulation intensity, comparator selection, monitoring requirements, bleeding definitions, and whether outcomes will focus on time in therapeutic range, coronary thrombosis, myocardial infarction, major bleeding, or composite end points. Because Kawasaki disease with large or giant aneurysms is uncommon, enrollment feasibility and international collaboration may also shape development.

References

1. Cadrenal Therapeutics. Cadrenal Therapeutics to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease. News release. Cadreinal Therapeutics. June 18, 2026. Accessed June 19, 2026. https://www.globenewswire.com/news-release/2026/06/18/3314211/0/en/cadrenal-therapeutics-to-file-for-fda-rare-pediatric-disease-designation-for-tecarfarin-in-kawasaki-disease.html
2. US Food and Drug Administration. Rare Pediatric Disease Priority Review Vouchers: Guidance for Industry. US Food and Drug Administration; 2019.
3. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-e999. doi:10.1161/CIR.0000000000000484
4. Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67(14):1738-1749. doi:10.1016/j.jacc.2015.12.073